Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NBIX 
Neurocrine Biosciences Inc (NBIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NBIX (1-star) is a SELL. SELL since 5 days. Profits (8.04%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $167.87
1 Year Target Price $167.87
| 15 | Strong Buy |
| 7 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.07% | Avg. Invested days 40 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.18B USD | Price to earnings Ratio 39.32 | 1Y Target Price 167.87 |
Price to earnings Ratio 39.32 | 1Y Target Price 167.87 | ||
Volume (30-day avg) 25 | Beta 0.25 | 52 Weeks Range 84.23 - 154.87 | Updated Date 08/15/2025 |
52 Weeks Range 84.23 - 154.87 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate 0.9784 | Actual 1.65 |
Profitability
Profit Margin 13.88% | Operating Margin (TTM) 21.18% |
Management Effectiveness
Return on Assets (TTM) 8.67% | Return on Equity (TTM) 13.39% |
Valuation
Trailing PE 39.32 | Forward PE 25.51 | Enterprise Value 12487024078 | Price to Sales(TTM) 5.25 |
Enterprise Value 12487024078 | Price to Sales(TTM) 5.25 | ||
Enterprise Value to Revenue 4.98 | Enterprise Value to EBITDA 22.41 | Shares Outstanding 99181504 | Shares Floating 98002242 |
Shares Outstanding 99181504 | Shares Floating 98002242 | ||
Percent Insiders 1.06 | Percent Institutions 101.06 |
Upturn AI SWOT
Neurocrine Biosciences Inc
Company Overview
History and Background
Neurocrine Biosciences Inc. was founded in 1992. The company is focused on discovering and developing innovative treatments for neurological, endocrine, and psychiatric disorders.
Core Business Areas
- Neurology: Focuses on treatments for neurological disorders such as tardive dyskinesia, Parkinson's disease, and essential tremor.
- Endocrinology: Deals with treatments for endocrine-related conditions, particularly women's health.
- Psychiatry: Concentrates on developing therapies for psychiatric disorders, like depression.
Leadership and Structure
Kevin Gorman is the CEO. The company operates with a functional organizational structure, with departments focused on research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- INGREZZA (valbenazine): INGREZZA is a selective vesicular monoamine transport 2 (VMAT2) inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease. It holds a significant market share in the TD treatment space. Competitors include Austedo (deutetrabenazine) by Teva and generics.
- ORILISSA (elagolix): ORILISSA is an oral GnRH antagonist used to treat moderate to severe endometriosis-associated pain. Market share is smaller than INGREZZA but growing. Competitors include AbbVie's Oriahnn and surgical interventions.
- KRYSTEXXA (pegloticase): KRYSTEXXA is for adults with uncontrolled gout. Competitors include allopurinol, febuxostat, and lesinurad.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive. The focus is on developing novel therapies to address unmet medical needs. Regulatory approvals and patent protection are critical for success.
Positioning
Neurocrine Biosciences Inc. is positioned as a leader in developing innovative treatments for neurological and endocrine-related disorders. Its competitive advantages include its expertise in VMAT2 inhibition and its strong pipeline of product candidates.
Total Addressable Market (TAM)
The total addressable market for Neurocrine's therapeutic areas is substantial, estimated to be in the billions of dollars. Neurocrine is positioned to capture a significant portion of this market through its innovative products and expanding commercial reach.
Upturn SWOT Analysis
Strengths
- Strong commercial product (INGREZZA)
- Deep expertise in neurological and endocrine disorders
- Robust pipeline of product candidates
- Strategic partnerships with other pharmaceutical companies
- Experienced management team
Weaknesses
- Dependence on a limited number of products
- High R&D expenses
- Regulatory risks associated with drug development
- Competition from established pharmaceutical companies
- Marketing and sales spend
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or companies
- Development of new formulations or delivery methods
- Increased adoption of INGREZZA for tardive dyskinesia
- Partnerships for global expansion
Threats
- Patent expiration and generic competition
- Unfavorable regulatory changes
- Failure of clinical trials
- Economic downturn affecting healthcare spending
- Increased competition in core therapeutic areas
Competitors and Market Share
Key Competitors
- TEVA
- ABBV
- SAGE
Competitive Landscape
Neurocrine competes with established pharmaceutical companies and generic manufacturers. Its competitive advantages include its expertise in VMAT2 inhibition and its strong pipeline of product candidates. Disadvantages include its dependence on a limited number of products.
Major Acquisitions
Syneos Health
- Year: 2024
- Acquisition Price (USD millions): 150
- Strategic Rationale: Expanded patient reach and access for INGREZZA
Growth Trajectory and Initiatives
Historical Growth: Neurocrine has experienced significant revenue growth over the past several years, driven primarily by INGREZZA sales.
Future Projections: Analysts project continued revenue growth for Neurocrine, driven by increased adoption of INGREZZA and the potential launch of new products. Growth rates are expected to moderate over time.
Recent Initiatives: Recent initiatives include expanding the commercial reach of INGREZZA, advancing product candidates in the pipeline, and strategic partnerships.
Summary
Neurocrine Biosciences is a strong pharmaceutical company with a promising future, primarily driven by the success of INGREZZA. The company's pipeline and strategic initiatives position it for continued growth. However, it needs to diversify its product portfolio and mitigate risks associated with patent expirations and competition. Regulatory risks are a persistent watch.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own due diligence and assessment of risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neurocrine Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1996-05-23 | CEO & Director Mr. Kyle W. Gano Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1800 | Website https://www.neurocrine.com |
Full time employees 1800 | Website https://www.neurocrine.com | ||
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.